D-CSS_Attach1_Purchase_Description.pdf

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

PURCHASE DESCRIPTION

1. Statement of Need and Purpose: Forty-four (44) bioactive compounds for replenishment and expansion of the Mechanism Interrogation Plate (MIPE) screening library for the NCATS.

2. Background Information and Objective: The National Center for Advancing Translational Sciences (NCATS), Division of Preclinical Innovation (DPI),NCATS, DPI, requires forty-four (44) bioactive compounds for replenishment and expansion of the Mechanism Interrogation Plate (MIPE) screening library.

DPI has a multidisciplinary team that developed a high-capacity robotic platform to screen drug combinations. In just a couple of days, the robots can perform a drug screen that would take human researchers months to complete. DPI develops and oversees the tests (called "assays") that run on the platform. The system performs the automated assays using diseased cells that are placed on plates in tiny indentations called wells.

Cells are treated in each well with a unique combination of drugs, and the assays reveal the effects of the drugs on each group of cells.

One feature that makes the platform stand out from previous combination drug screening efforts is the drug library it uses, called the MIPE. All the drugs in the MIPE collection are relevant for clinical use in cancer and have mechanisms of action that scientists already understand. The observations of each drug pair’s effects on the target cells, coupled with the detailed knowledge about the compounds in the MIPE library, provide the researchers with insights into the interactions between various cellular processes. This library not only enables DPI to find compound combinations that can go rapidly into clinical trials, but also explore the biological processes that create the enhanced effect of a drug combination in a cell, leading to new drug targets.

The evolution of the MIPE library requires regular updating with new agents. The MIPE

6.0 expansion will incorporate the new agents that are the subject of this acquisition and further the potential of chemogenomic screening at NCATS. Expanding the MIPE screening library with these forty-four (44) bioactive compounds is critical for meeting the needs of NCATS.

3. Generic Name of Product: Bioactive agents.

4. Purchase Description: Brand-name or equal to the following:

Product’s brand name: Forty-four (44) Bioactive Compounds.

Product’s Manufacturer: MedChemExpress LLC, 18 Wilkinson Way, Princeton, NJ 08540-7346.

Manufacturer’s catalog number (i.e. Supplier ID) and the chemical description from the Chemical Abstract Service (CAS) for each compound are as follow:

Name Supplier ID CAS Unit Size Quantity

Derenofylline HY-14858 251945-92-3 5mg 1 SR-3306 HY-12829 1128096-91-2 5mg 1 Gefitinib-based PROTAC 3 HY-123921 2230821-27-7 10mg 1 Anisina HY-100948B 1861449-70-8 10mg 1 ALW-II-41-27 HY-18007 1186206-79-0 5mg 1 BMS-1166 HY-102011 1818314-88-3 5mg 1 LY-2857785 HY-12293 1619903-54-6 5mg 1 OSU-T315 HY-18676 1333146-24-9 5mg 1 MD-224 HY-114312 2136247-12-4 10mg 1 Supinoxin HY-123611 888478-45-3 5mg 1 HG-6-64-1 HY-12291 1315329-43-1 5mg 1 PTC-691 HY-15961 420126-30-3 5mg 1 GMB-475 HY-125834 None assigned 10mg 1 S-64315 HY-112218 1799631-75-6 10mg 1 ACBI-1 HY-128359 2375564-55-7 10mg 1 BETd-260 HY-101519 2093388-62-4 10mg 1 MZP-55 HY-112377 2010159-48-3 10mg 1 MZP-54 HY-112376 2010159-47-2 10mg 1 Motixafortide HY-P0171 664334-36-5 25mg 1 Voclosporin HY-106638 515814-01-4 10mg 1 BETd-246 HY-115568 2140289-17-2 10mg 1 ADU-S100 HY-12885A 1638750-95-4 10mg 1 Dolastatin 10 HY-15580 110417-88-4 5mg 2 GNE-987 HY-129937A None assigned 10mg 1 JH-XI-10-02 HY-111518 2209085-22-1 10mg 1 BI-3663 HY-111546 2341740-84-7 10mg 1 Eribulin HY-13442A 441045-17-6 10mg 1 Lurbinectedin HY-16293 497871-47-3 2mg 3 BI605906 HY-13019 960293-88-3 10mg 1 BAI1 HY-103269 335165-68-9 10mg 1 Pelcitoclax HY-109185 None assigned 10mg 1 HA14-1 HY-12011 65673-63-4 50mg 1 Maritoclax HY-15613 1227962-62-0 10mg 1 S65487 HY-138697 1644600-79-2 10mg 1

Necrosulfonamide HY-100573 1360614-48-7 25mg 1 GSK2983559 HY-19764 1423186-80-4 10mg 1 JNJ-67856633 HY-139399 2230273-76-2 10mg 1 Phorbol 12-myristate 13-acetate (PMA) HY-18739 16561-29-8 25mg 1 MLT-943 HY-134820 1832576-04-1 10mg 1 T6167923 HY-19744 2437475-16-4 10mg 1 MLT-748 HY-115466 1832578-30-9 10mg 1 TC13172 HY-101524 2093393-05-4 10mg 1 Alflutinib HY-112870A 2130958-55-1 10mg 1 ALDH1A1-IN-2 HY-126003 2231081-18-6 10mg 1

5. Salient characteristics: Brand equal products must meet the following salient physical, functional, or performance characteristics to be eligible for award:

• Quantity and weight as listed above.

• Confirmed purity greater than 98% (>98).

• Meet the chemical description under the CAS. The CAS Registry Numbers are unique numerical identifiers assigned by the CAS to every chemical described in the open scientific literature and including elements, isotopes, organic and inorganic compounds, ions, organometallics, metals, nonstructurable materials.

• Include the Quality Control (QC) information such as liquid chromatography-mass spectrometry (LCMS) and H1 nuclear magnetic resonance (NMR) data for all agents. This includes the high-performance liquid chromatography (HPLC) purity trace, low-resolution mass spectral signature and proton NMR.

6. Quantity: As listed above.

7. Delivery Date: Within fifty (50) days after receipt of order (ARO).

PURCHASE DESCRIPTION